Phase III trial results of the R21/Matrix-M vaccine developed by Oxford University and Serum Institute of India Pvt Ltd, leveraging Novavax’s Matrix-M adjuvant, has confirmed high efficacy and supported regulatory approvals and licensure in several African countries.
Leave A Comment